Skye Bioscience, Inc. — Director's Dealing 2018

Jan 29, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Nemus Bioscience, Inc. (NMUS)
CIK: 0001516551
Period of Report: 2018-01-18

Reporting Person: Emerald Health Sciences Inc. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	24000000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Convertible Preferred Stock	$0.10		Common Stock (12335000)		Direct
Series F Convertible Preferred Stock	$0.10		Common Stock (20000000)		Direct
Common Stock Warrants (right to buy)	$0.10	2023-01-18	Common Stock (20400000)		Direct

Footnotes

F1: The Series B Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date, subject to certain restrictions on beneficial ownership percentages.

F2: The Series F Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date, subject to certain restrictions on beneficial ownership percentages.